American Association of Clinical Endocrinology Communities Middle East & North Africa 2025

Description

+ Include: 56 videos + 56 file sub vtt + 54 pdfs, size: 23.46 GB

+ Target Audience: endocrinologists and primary care physicians

+ Sample video: contact me for sample video

+ Information:

1. Overview

The American Association of Clinical Endocrinology Communities Middle East & North Africa 2025 program provides a comprehensive review of the latest advancements in endocrinology. It covers critical updates in diabetes management technologies, obesity pharmacotherapy, thyroid cancer, menopause, and bone health, with special clinical considerations for regional practices such as managing patients during Ramadan.

The three-day event provided a platform for regional and international endocrinology leaders to collaborate and discuss advancements in diabetes, thyroid, bone, pituitary, adrenal, and metabolic health. It featured over 50 educational sessions and hands-on workshops tailored to the unique clinical challenges of the MENA region.

Course Date: November 21–23, 2025, at the InterContinental Dubai Festival City, United Arab Emirates

2. Learning Objectives

By the end of the meeting, you will be able to:

• Demonstrate the understanding of a multidisciplinary approach, including lifestyle and nutrition in the effective management of metabolic diseases.
• Gain insight and skills in implementation of self-management tools, new medications, AI and technology for improved outcomes in Diabetes.
• Demonstrate appreciation and understanding of bone mineral disorders.
• Explore the latest clinical guidelines for thyroid nodules and cancer, and engage in case-based learning of complex thyroid issues.
• Review and apply evidence-based strategies for assessment and management of pituitary and adrenal conditions.
• Integrate multidisciplinary approaches for improved care and treatment of endocrine disorders.
• Evaluate, understand, and manage women’s health and menopause.

3. Target Audience

Best for endocrinologists and primary care physicians who want updates on diabetes management, obesity therapies, and thyroid disorders.

4. Topics

1. Closing Remarks

2. IDS1.A.1 CGM Use in People With and Without Diabetes

3. IDS1.A.2 SGLT2i Use in Type 1 DM

4. IDS1.A.3 GLP1 use in T1DM

5. IDS1.B.1 Menopause Hormone Therapy 101

6. IDS1.B.2 Mood, Sleep and Cognitive Function in Menopause

7. IDS1.B.3 Menopause and Cardiometabolic Risk

8. IDS1.C.1 Molecular Basis of Thyroid Cancer and its Translational Implications

9. IDS1.C.2 What’s New in Medullary Thyroid Cancer

10. IDS1.C.3 Contemporary Management of Graves’ Disease

11. IDS2.A.1 Diabetes and Ramadan An Update

12. IDS2.A.2 Thyroid and Ramadan In Health and Disease

13. IDS2.A.3 Adrenal Replacement in Ramadan

14. IDS2.B.1 Obesity Management in Adolescent

15. IDS2.B.2 From Fat Storage to Fat Burning Exploring the Role of Fasting in Obesity Treatment

16. IDS2.B.3 Approaching Weight Management in Women of Childbearing Age

17. IDS2.C.1 Smoking and Bone Health

18. IDS2.C.2 Osteoporosis in Men

19. IDS2.C.3 Bone Health in Cancer Patients

20. IDS2.D.1 Diabetes Management in the Older Adult

21. IDS2.D.2 Obesity Management in the Elderly

22. IDS2.D.3 When to Treat and When Not to Treat for Thyroid Disease in Geriatrics

23. IDS3.A.1 Mild Autonomous Cortisol Secretion MACS

24. IDS3.A.2 Adrenocortical Cancer New Advances

25. IDS3.A.3 Regional Barriers to Diagnosis and Management of Adrenal Insufficiency

26. IDS3.B.1 Obesity Management in Persons with Special Needs

27. IDS3.B.2 Metabolic and Bariatric Management in Pediatrics

28. IDS3.B.3 Turners Syndrome

29. MTE1.A What’s New in the Approach and Management of Pheochromocytoma Paraganglioma

30. MTE1.B Pituitary Tumors, Biology and Clinical Classification

31. MTE1.C Treatment of Osteoporosis in the Oldest Old

32. MTE2.A Prevention and Cure, Current and Future for Type 1 Diabetes

33. MTE2.B Management of Kidney Disease in Diabetes – An Update

34. MTE2.C Endocrine Practice in Resource – Limited Settings

35. MTE3.A Screening & Management of Metabolic Liver Disease in Endocrine Clinics

36. MTE3.B What is in the Pipeline for Diabetes and Obesity Management

37. MTE3.C Islet Cell Transplant, Innovations in Type 1 Diabetes Management

38. MTE3.D Remission of T2D Through Diet – Is it Real

39. MTE4.ASurgicalHypoparathyroidism

40. MTE4.B Thyroid Autoimmunity and Cardiovascular Risk Beyond Hypothyroidism

41. MTE4.C Beyond BMI The Role of Body Composition Assessment in Obesity Pharmacotherapy

42. MTE4.D Testosterone Replacement – Indications and Challenges

43. MTE5.A Primary Aldosteronism

44. MTE5.B What is the Role for Lifestyle Support in the New Era of Medical Treatment for Obesity

45. MTE5.C Parathyroid in Pregnancy

46. PL1. Acromegaly, Diagnosis, Management and Anomalies

47. PL2. Understanding Sexual Dysfunction in Women with Obesity and Diabetes

48. PL3. Updated Thyroid Nodule and Cancer Guidelines, An Endocrine Surgeon’s Perspective

49. PL4. Indications for SGLT2I and Incretin-Based Therapy Beyond Diabetes Overview and Future Outlook

50. PL5. Congenital Adrenal Hyperplasia

51. PL6. Diagnosis and Management of Hypoparathyroidism

52. PL7. Breaking the Cycle From Fat Cells and Gut to the Mind in Weight Regain

53. Roundtable Discussion – Ali Alzahrani

54. Roundtable Discussion – Samer El-Kaissi

55. Roundtable Discussion – Tamer Elsherbiny

56. Welcome and Opening Ceremony